logo

For the Inventor, By the Inventor

Fujian, China

Fuwen Xie

USPTO Granted Patents = 12 

 

Average Co-Inventor Count = 3.9

ph-index = 1

Forward Citations = 3(Granted Patents)


Location History:

  • Long Yan, CN (2015 - 2016)
  • Fujian, CN (2015 - 2018)

Company Filing History:

goldMedal11 out of 11 
 
Hangzhou Bensheng Pharmaceutical Co., Ltd.
 patents
silverMedal1 out of 1 
 
Hangzhou Bensheng Pharmaceuticals Co., Ltd.
 patent

Years Active: 2015-2018

Loading Chart...
Loading Chart...
12 patents (USPTO):Explore Patents
1. 9902736 - 1-oxo/acylation-14-acylated oridonin derivative, preparation method therefor and application thereof (2018-02-27),
2. 9771343 - 2-alkyl-or-aryl-substituted tanshinone derivatives, and preparation method and application thereof (2017-09-26),
3. 9676789 - Aminated derivative of homoharringtonine, preparation method therefor, and application thereof (2017-06-13),
4. 9428519 - Acylated derivative of homoharringtonine, preparation method therefor, and application thereof (2016-08-30),
5. 9353146 - Acylation derivatives of paridis saponins I, preparation method therefor and application thereof (2016-05-31),
6. 9328122 - 7-substituted Hanfangichin B derivative, and preparation method and use thereof (2016-05-03),
7. 9328083 - 2-aminated methylene or 2-esterified methylene tanshinone derivatives, and preparation method and application thereof (2016-05-03),
8. 9249137 - Dicarboximide derivatives of berbamine, the preparation and use thereof (2016-02-02),
9. 9156801 - 2-substituted oleanolic acid derivative, method preparing for same, and application thereof (2015-10-13),
10. 9133207 - Tetrandrine derivatives with substituted 5-carbon, preparation method and use thereof (2015-09-15),
11. 8987502 - Oleanolic acid amidate derivatives, preparation methods and uses thereof (2015-03-24),
12. 8987288 - Heterocyclic aminoberbamine derivatives, the preparation process and use thereof (2015-03-24),

Title: The Innovative Contributions of Fuwen Xie

Introduction

Fuwen Xie is a noteworthy inventor hailing from Fujian, China, with a remarkable portfolio comprising 12 patents. His contributions primarily focus on the fields of natural medicine and medicinal chemistry, showcasing his commitment to advancing healthcare through innovative solutions.

Latest Patents

Fuwen Xie's latest patents include groundbreaking developments in pharmaceutical compounds. One significant invention is the 1-oxo/acylation-14-acylated oridonin derivative, which relates to the preparation of antitumor drugs. This invention includes a general formula for these compounds and outlines a preparation method that is expected to enhance the efficacy of natural medicines.

Another of his notable patents covers 2-alkyl- or aryl-substituted tanshinone derivatives. This invention also targets the field of natural medicine and pharmaceutical chemistry. The derivative compounds developed by Xie are aimed at formulations for antineoplastic medicaments, illustrating his innovative approach to tackling complex medical challenges.

Career Highlights

Fuwen Xie's career features significant contributions in pharmaceutical companies, notably Hangzhou Bensheng Pharmaceutical Co., Ltd. and Hangzhou Bensheng Pharmaceuticals Co., Ltd. Through his work in these firms, he has continually pushed the boundaries of research and innovation in the field of medicinal chemistry.

Collaborations

Xie has collaborated with prominent individuals in his field, including notable colleagues such as Rongzhen Xu and Frank Rong. Their combined expertise has likely amplified the impact of their shared projects and advancements in medicinal compounds.

Conclusion

Fuwen Xie stands out as a driving force in the realm of innovation within natural medicine. His extensive patent portfolio reflects a dedication to improving healthcare solutions, particularly in the development of antitumor and antineoplastic agents. With a continued focus on research and collaboration, his future contributions are poised to further enhance advancements in medicinal chemistry.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to support@idiyas.com
Loading…